Literature DB >> 1444194

Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point.

T Furukawa1, T Kubota, M Watanabe, S Kase, T Takahara, H Yamaguchi, T Takeuchi, T Teramoto, K Ishibiki, M Kitajima.   

Abstract

Three-dimensional histoculture with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide (MTT) end-point was utilized for chemosensitivity testing of 100 clinical gastrointestinal cancers and the results were compared with those obtained with cell-suspension culture with the MTT end-point. Of the 100 surgical specimens, 91 were evaluable using histoculture assay and 66 were evaluable using the cell-suspension assay. When the assay results were compared with historical frequency of clinical response to chemotherapy, the results of the histoculture assay showed a closer correlation than those of the cell-suspension assay. Therefore, the histoculture assay seems to have a higher evaluability rate and a closer correlation with clinical chemosensitivity of gastrointestinal cancers than the cell-suspension assay.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444194

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question.

Authors:  Tetsuro Kubota; Larry Weisenthal
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

Review 2.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

3.  Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification.

Authors:  H Kobayashi; M Higashiyama; K Minamigawa; K Tanisaka; T Takano; H Yokouchi; K Kodama; T Hata
Journal:  Jpn J Cancer Res       Date:  2001-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.